Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Downregulated AKT-mTOR signaling pathway proteins in dorsolateral prefrontal cortex in Schizophrenia
Radhika Chadha, James H. Meador‐Woodruff
Neuropsychopharmacology (2020) Vol. 45, Iss. 6, pp. 1059-1067
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Oxidative Stress‐Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives
Evgeny A. Ermakov, E. Dmitrieva, D. Parshukova, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 170
Targeting PI3K-AKT/mTOR signaling in the prevention of autism
Aarti Sharma, Sidharth Mehan
Neurochemistry International (2021) Vol. 147, pp. 105067-105067
Closed Access | Times Cited: 88
PI3K-AKT/mTOR Signaling in Psychiatric Disorders: A Valuable Target to Stimulate or Suppress?
Yan Chen, Wei Guan, Meilan Wang, et al.
The International Journal of Neuropsychopharmacology (2024) Vol. 27, Iss. 2
Open Access | Times Cited: 15
CDGSH iron sulfur domain 2 over‐expression alleviates neuronal ferroptosis and brain injury by inhibiting lipid peroxidation via AKT/mTOR pathway following intracerebral hemorrhage in mice
Ruihao Li, Xingyu Zhang, Lingui Gu, et al.
Journal of Neurochemistry (2023) Vol. 165, Iss. 3, pp. 426-444
Closed Access | Times Cited: 15
Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia
Chuanjun Zhuo, Qiuyu Zhang, Lina Wang, et al.
CNS Drugs (2023) Vol. 38, Iss. 1, pp. 33-44
Open Access | Times Cited: 14
mTOR kinase activity disrupts a phosphorylation signaling network in schizophrenia brain
Radhika Chadha, Khaled Alganem, Robert E. McCullumsmith, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 11, pp. 6868-6879
Closed Access | Times Cited: 28
Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats
Dalia A. Nawwar, Hala F. Zaki, Rabab H. Sayed
Inflammopharmacology (2022) Vol. 30, Iss. 5, pp. 1891-1907
Open Access | Times Cited: 21
Study on correlations of BDNF, PI3K, AKT and CREB levels with depressive emotion and impulsive behaviors in drug-naïve patients with first-episode schizophrenia
Shan Li, Cailian Lu, Lin Kang, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
The stress–Wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches
Cristine Marie Yde Ohki, Leoni Grossmann, Emma Alber, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 30
Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K/AKT/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells
Afnan H. El‐Gowily, Samah A. Loutfy, Ehab M. M. Ali, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 3, pp. 254-254
Open Access | Times Cited: 25
Schizophrenia and psychedelic state: Dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes
Jacopo Sapienza, Marta Bosia, Marco Spangaro, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 59-67
Closed Access | Times Cited: 19
S1P/S1PR1 signaling differentially regulates the allogeneic response of CD4 and CD8 T cells by modulating mitochondrial fission
Linlu Tian, Yongxia Wu, Hee-Jin Choi, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 11, pp. 1235-1250
Open Access | Times Cited: 18
AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology
Apostolia M. Tsimberidou, Antonis Skliris, Alan Valentine, et al.
Cell & Bioscience (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 17
Exosomes in schizophrenia: Pathophysiological mechanisms, biomarkers, and therapeutic targets
Yu Wang, Nousayhah Amdanee, Xiangrong Zhang
European Psychiatry (2022) Vol. 65, Iss. 1
Open Access | Times Cited: 17
Research Progress on Cognitive Impairment in Schizophrenia
曦元 张
Advances in Clinical Medicine (2025) Vol. 15, Iss. 04, pp. 1070-1079
Closed Access
Ribosomal Protein S6 Hypofunction in Postmortem Human Brain Links mTORC1-Dependent Signaling and Schizophrenia
Inés Ibarra‐Lecue, Rebeca Dı́ez-Alarcia, Benito Morentín, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 24
Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients
Inés Ibarra‐Lecue, Paula Unzueta‐Larrinaga, R. Barrena-Barbadillo, et al.
Addiction Biology (2022) Vol. 27, Iss. 6
Open Access | Times Cited: 16
Effects of icariin on alleviating schizophrenia-like symptoms by regulating the miR-144-3p/ATP1B2/mTOR signalling pathway
Bo Pan, Lianlian Xu, Jianjun Weng, et al.
Neuroscience Letters (2022) Vol. 791, pp. 136918-136918
Closed Access | Times Cited: 15
Exosome and exosomal contents in schizophrenia
Tingkai Zhang, Yehong Fang, Liangliang Wang, et al.
Journal of Psychiatric Research (2023) Vol. 163, pp. 365-371
Closed Access | Times Cited: 9
Peripheral blood MicroRNAs as biomarkers of schizophrenia: expectations from a meta-analysis that combines deep learning methods
Shiyuan Han, Yongning Li, Jun Gao
The World Journal of Biological Psychiatry (2023) Vol. 25, Iss. 1, pp. 65-81
Closed Access | Times Cited: 9
Unlocking new avenues for neuropsychiatric disease therapy: the emerging potential of Peroxisome proliferator-activated receptors as promising therapeutic targets
Asmita Deka Dey, Ashi Mannan, Sonia Dhiman, et al.
Psychopharmacology (2024) Vol. 241, Iss. 8, pp. 1491-1516
Closed Access | Times Cited: 3
Psychedelics and schizophrenia: a double-edged sword
Jacopo Sapienza, Francesca Martini, Stefano Comai, et al.
Molecular Psychiatry (2024)
Closed Access | Times Cited: 3
The prefrontal cortex as a target for atypical antipsychotics in schizophrenia, lessons of neurodevelopmental animal models
Hiram Tendilla‐Beltrán, Nydia del Carmen Sanchez-Islas, Mauricio Marina-Ramos, et al.
Progress in Neurobiology (2020) Vol. 199, pp. 101967-101967
Closed Access | Times Cited: 23
Altered expression levels of miR-144-3p and ATP1B2 are associated with schizophrenia
Bo Pan, Yuting Wang, Yiwen Shi, et al.
The World Journal of Biological Psychiatry (2022) Vol. 23, Iss. 9, pp. 666-676
Closed Access | Times Cited: 13
Comparative psychopharmacology of autism and psychotic-affective disorders suggests new targets for treatment
Bernard J. Crespi
Evolution Medicine and Public Health (2019) Vol. 2019, Iss. 1, pp. 149-168
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top